Business
Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
Former Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development Expertise NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) --
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"Former Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development Expertise\nNEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (\"Indaptus\" or the \"Company”), today announces the appointment of Mark Gilbert, M.D., to its Board of Directors. Dr. Gilbert served as Chief Medical Officer of Juno Therapeutics prior to its acquisition by Celgene Corporation and currently serves as Executive Vice President of Research and Development at Acepodia. He succeeds outgoing Director Hoonmo Lee, who has stepped down from Indaptus’ Board as part of the transition, effective upon Dr. Gilbert’s appointment. “We are delighted to have Dr. Gilbert join the Indaptus Board of Directors. His successful record of shepherding Juno’s novel CAR-T technology from bench to bedside brings valuable experience to the Indaptus Board. The Company looks forward to benefiting from his experience as we advance our new modality immunotherapy pipeline into and through the clinic,” said Jeffrey Meckler, Chief Executive Officer of Indaptus. “In addition, we thank Mr. Lee for his service to our Board and wish him well in his future endeavors.” “I am excited to join the Indaptus Board of Directors, as I believe their novel, multi-TLR agonist therapeutic designed to safely prime and activate both the innate and adaptive immune systems has the potential to change oncology treatment paradigms and improve currently available immuno-oncology therapeutics. I look forward to bringing my experience advancing CAR-T therapies to bear with my fellow Directors and Senior Management as we guide Indaptus into the clinic and beyond,” said Dr. Gilbert. Prior to joining Acepodia, Dr. Gilbert was Chief Medical Officer of Juno Therapeutics where he led the clinical development of some of the first CAR-T cell therapies. Before that, he held leadership positions at Bayer Schering Pharmaceuticals, Berlex Pharmaceuticals, Schering AG, and Immunex. Prior to his pharmaceutical industry positions, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington, where he trained in the laboratory of Dr. Phil Greenberg, a scientific co-founder of Juno Therapeutics. Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and an M.D. from the University of Iowa Medical...